Highest-materiality recent filing
Kettner Investments acquires control via Series C Preferred Stock transfer from Juniper & Ivy and Medical Marijuana, Inc.
AXIM issues $814,555 in convertible notes and restricted stock for past-due compensation
Issued $814,555 convertible notes to directors, officers, contractors, and Sapphire employees to settle past salaries/fees.
AXIM Biotechnologies settles IMS litigation; to issue 20M restricted shares plus cash and royalties
Settlement with Innovative Medical Supplies resolves two lawsuits; no admission of wrongdoing.
Axim Biotech enters up to $750K convertible note deal with affiliate Medical Marijuana Inc
Initial $100,000 note issued Dec 26, 2023; MJNA can purchase up to $750,000 total by June 26, 2025.
AXIM Biotechnologies enters $20M equity purchase agreement with Cross & Company
Equity Purchase Agreement for up to $20M of common stock with an institutional investor (Cross & Company).
Aggregate principal of $575,000: $325,000 cash from four notes, $250,000 to repay prior advances.
AXIM Biotechnologies appoints Kurt Phinney as COO; grants option for 2M shares
Kurt Phinney appointed COO effective May 23, 2023; minimum six-month term.
AXIM cures defaults on $5.3M in debt, cuts conversion prices, gives CEO $250K note for back pay
TL-66 waives $216,572 interest on $934,478 secured notes; conversion price cut to $0.04 from $0.2201.
AXIM signs exclusive global licensing deal with Verséa for dry eye diagnostic tests
Five-year License and Distribution Agreement with Verséa for global sale of AXIM's point-of-care ocular diagnostics.
AXIM issues 13.86M restricted shares in two private placements for $350K total
Issued 3,861,004 restricted shares to affiliate Catalina Valencia for $100,000 ($0.0259/share).
AXIM shifts COVID-19 NAb test to RUO; separates from Empowered Diagnostics
COVID-19 NAb test now offered For Research Use Only after FDA changed priorities from qualitative testing.
AXIM raises $1.825M in new debt; retires $1.11M GS Capital note
Issued two $250K short-term notes (1.5% interest, due March 10, 2022); one repaid on Feb 14.
AXIM appoints Blake N. Schroeder as director to fill vacancy, effective Jan 6, 2022
Schroeder replaces Mauricio Javier Gatto-Bellora, appointed by written consent of Series C preferred stockholder.
AXIM Biotechnologies director Mauricio Gatto Bellora resigns
Mauricio Gatto Bellora resigned from the Board of Directors effective January 4, 2022.
AXIM Biotech signs binding term sheet to acquire FDA-cleared dry eye tests, paying 7M shares
AXIM to acquire two FDA-cleared dry eye diagnostic tests from Advanced Tear Diagnostics for 7M restricted shares.
effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy
Due to the fact that the Company's President and CEO, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness
On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness.
on October 9, 2024, the Company’s board of directors appointed Catalina Valencia as the Company’s new President.
On May 23, 2023, our Chief Executive Officer appointed Kurt Phinney as the Company’s Chief Operating Officer.
consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto-Bellora.
consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto-Bellora.
On January 4, 2022, Mauricio Gatto Bellora tendered his resignation as a member of the Board of Directors of AXIM Biotechnologies, Inc. (the "Company"), and the Company on that date accepted his resignation.
Max materiality 0.90 · Median 0.55 · Most common event other_material